THIOLA® (tiopronin) tablets

THIOLA® is indicated for the prevention of cystine kidney stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to

THIOLA® is contraindicated during pregnancy (except where the benefits clearly outweigh the risks), in nursing mothers, and in patients who have previously developed agranulocytosis, aplastic anemia or thrombocytopenia while on this medication.1

THIOLA® is associated with fewer or less severe reactions than d-penicillamine, however the following adverse reactions, or types of reactions, may occur: Gastrointestinal; Impairment in taste or smell; Dermatologic; Hypersensitivity; Hematologic; Renal; Pulmonary; and Neurologic.1 Please see full prescribing information for Thiola® (tiopronin) tablets. (for U.S. audiences)

Patients who are interested in treatment with THIOLA® are encouraged to first consult a licensed healthcare professional. Additional information about starting treatment with THIOLA® is available through our Thiola Total Care HUB® (1-844-484-4652). This free support program dedicated to patients eases access to therapy, while providing live, on-demand support from dedicated pharmacists and HUB counselors to answer product questions, and assist with insurance verification, reimbursement options, and financial support.

We offer co-pay assistance and provide free medication to those who qualify, as part of our patient assistance program.

For medical inquiries and product complaints, contact Retrophin at 1-877-659-5518.

To report suspected adverse reactions, contact Retrophin at 1-877-659-5518 or
FDA at 1-800-FDA-1088 or


  1. THIOLA® (tiopronin) tablets [prescribing information]. San Antonio, TX. Mission Pharmacal Company.